Left ventricular hypertrophy: Risk factor or preclinical disease?
Diabetes Mellitus, Type 2
Hypertrophy, Left Ventricular
Although left ventricular hypertrophy (LVH) has been traditionally classified as a cardiovascular risk factor, recent studies suggest that this anatomic abnormality is more appropriately considered as a form of 'preclinical cardiovascular disease.' It is now well established that LVH develops in some but not all patients with hypertension, obesity or other risk factors, indicating that it is only incompletely coupled to conventional risk factors. In turn, individuals who develop LVH in the general population or among patients with hypertension, coronary artery disease, or other diseases are at 2- to 4-fold higher risk of myocardial infarction, stroke, or cardiac death than their counterparts without LVH. Thus, LVH is more strongly related to adverse cardiovascular events than are hypertension, dyslipidemia, or other conventional risk factors, indicating that it represents a clinically important form of preclinical cardiovascular disease in asymptomatic individuals.